RT @JuanGrvas: @nomecreonadatv @RaulCalvoRico Pues una comentario que echaba de menos @RaulCalvoRico sobre sacubitrilo/valsartan. En este c…
@nomecreonadatv @RaulCalvoRico Pues una comentario que echaba de menos @RaulCalvoRico sobre sacubitrilo/valsartan. En este caso su introducción tras la hospitalización con insuficiencia cardíaca y fracción de eyección preservada...PERO es un estudio "post-
New NNT→Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared With Valsartan in HFpEF. https://t.co/DbIyDoD7Va
RT @mvaduganathan: New #PARAGONHF data @AHAMeetings #AHA19 now online in @JACCJournals w/ @scottdsolomon Relative & absolute benefits of…
RT @DrRajivsankar: In the PARAGON-HF trial, the relative and absolute benefits of sacubitril/valsartan compared with valsartan in #HFpEF ap…
RT @FH_Verbrugge: Remarkable result: Sacubitril/Valsartan in #HFpEF only seemed to benefit patients with a recent (<30 days) hospitalisatio…
Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared With Valsartan in HFpEF https://t.co/v8DRcFt853
Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared With Valsartan in HFpEF. - PubMed - NCBI https://t.co/MV6Hp1RMvU
Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared With Valsartan in HFpEF. - PubMed - NCBI https://t.co/tErIzAag5W
RT @JACCJournals: Drs. @scottdsolomon, @mvaduganathan, @svperrone et al. find benefits of sacubitril/valsartan (vs. valsartan) in #HFpEF ap…
RT @paolabel_cardio: Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared With Valsartan i…
RT @JACCJournals: Drs. @scottdsolomon, @mvaduganathan, @svperrone et al. find benefits of sacubitril/valsartan (vs. valsartan) in #HFpEF ap…
RT @JACCJournals: Drs. @scottdsolomon, @mvaduganathan, @svperrone et al. find benefits of sacubitril/valsartan (vs. valsartan) in #HFpEF ap…
RT @JACCJournals: Drs. @scottdsolomon, @mvaduganathan, @svperrone et al. find benefits of sacubitril/valsartan (vs. valsartan) in #HFpEF ap…
RT @JACCJournals: Drs. @scottdsolomon, @mvaduganathan, @svperrone et al. find benefits of sacubitril/valsartan (vs. valsartan) in #HFpEF ap…
RT @JACCJournals: Drs. @scottdsolomon, @mvaduganathan, @svperrone et al. find benefits of sacubitril/valsartan (vs. valsartan) in #HFpEF ap…
RT @JACCJournals: Drs. @scottdsolomon, @mvaduganathan, @svperrone et al. find benefits of sacubitril/valsartan (vs. valsartan) in #HFpEF ap…
RT @JACCJournals: Drs. @scottdsolomon, @mvaduganathan, @svperrone et al. find benefits of sacubitril/valsartan (vs. valsartan) in #HFpEF ap…
Drs. @scottdsolomon, @mvaduganathan, @svperrone et al. find benefits of sacubitril/valsartan (vs. valsartan) in #HFpEF appear to be amplified when initiated in high-risk window after hospitalization. Read their study, first presented at #AHA19 in #JACC. ht
RT @ValleAlfonso: Gradient in RRR in primary events with sacubitril/valsartan from patients hospitalized 🏨within 30 days (rate ratio: 0.73;…
ARNI benefits more following hospitalization with HFpEF within 30 days, in post-hoc analysis. Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared With Valsartan in HFpEF https://t.co/pjBatCAcc2
RT @ValleAlfonso: Gradient in RRR in primary events with sacubitril/valsartan from patients hospitalized 🏨within 30 days (rate ratio: 0.73;…
RT @DrRajivsankar: In the PARAGON-HF trial, the relative and absolute benefits of sacubitril/valsartan compared with valsartan in #HFpEF ap…
RT @DrRajivsankar: In the PARAGON-HF trial, the relative and absolute benefits of sacubitril/valsartan compared with valsartan in #HFpEF ap…
RT @ValleAlfonso: Gradient in RRR in primary events with sacubitril/valsartan from patients hospitalized 🏨within 30 days (rate ratio: 0.73;…
RT @ValleAlfonso: Gradient in RRR in primary events with sacubitril/valsartan from patients hospitalized 🏨within 30 days (rate ratio: 0.73;…
RT @DrRajivsankar: In the PARAGON-HF trial, the relative and absolute benefits of sacubitril/valsartan compared with valsartan in #HFpEF ap…
RT @ValleAlfonso: Gradient in RRR in primary events with sacubitril/valsartan from patients hospitalized 🏨within 30 days (rate ratio: 0.73;…
Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared With Valsartan in HFpEF https://t.co/v8DRcFt853
RT @DrRajivsankar: In the PARAGON-HF trial, the relative and absolute benefits of sacubitril/valsartan compared with valsartan in #HFpEF ap…
RT @ValleAlfonso: Gradient in RRR in primary events with sacubitril/valsartan from patients hospitalized 🏨within 30 days (rate ratio: 0.73;…
RT @DrRajivsankar: In the PARAGON-HF trial, the relative and absolute benefits of sacubitril/valsartan compared with valsartan in #HFpEF ap…
RT @ValleAlfonso: Gradient in RRR in primary events with sacubitril/valsartan from patients hospitalized 🏨within 30 days (rate ratio: 0.73;…
RT @DrRajivsankar: In the PARAGON-HF trial, the relative and absolute benefits of sacubitril/valsartan compared with valsartan in #HFpEF ap…
In the PARAGON-HF trial, the relative and absolute benefits of sacubitril/valsartan compared with valsartan in #HFpEF appear amplified in the high risk window after hospitalisation first Decompensated #heartfailure https://t.co/M8jm8fMWLZ
RT @ValleAlfonso: Gradient in RRR in primary events with sacubitril/valsartan from patients hospitalized 🏨within 30 days (rate ratio: 0.73;…
Remarkable result: Sacubitril/Valsartan in #HFpEF only seemed to benefit patients with a recent (<30 days) hospitalisation. Results from PARAGON-HF in @JACCJournals
RT @ValleAlfonso: Gradient in RRR in primary events with sacubitril/valsartan from patients hospitalized 🏨within 30 days (rate ratio: 0.73;…
RT @ValleAlfonso: Gradient in RRR in primary events with sacubitril/valsartan from patients hospitalized 🏨within 30 days (rate ratio: 0.73;…
RT @ValleAlfonso: Gradient in RRR in primary events with sacubitril/valsartan from patients hospitalized 🏨within 30 days (rate ratio: 0.73;…
Gradient in RRR in primary events with sacubitril/valsartan from patients hospitalized 🏨within 30 days (rate ratio: 0.73; 95% confidence interval: 0.53 to 0.99) to patients never hospitalized🏥⛔️ in #HFpEF @secardiologia @mvaduganathan @scottdsolomon 📎ht
Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared With Valsartan in HFpEF https://t.co/mypcVeFnFS
5th paper from Prof John McMurray "Prior Heart Failure Hospitalization,Clinical Outcomes & Response to Sacubitril/Valsartan Compared with Valsartan in HFpEF" @JACCJournals https://t.co/CQIjvk1wDg Congrats to all for having 5 papers in 2 leading cardiol
RT @JACCJournals: @mvaduganathan presents PARAGON-HF substudy to packed audience at #AHA19: Benefits of sacubitril/valsartan (vs. valsartan…
RT @MAROSFO: the sooner the better? 📌 In the PARAGON-HF trial, relative and absolute benefits appear to be amplified when initiated in the…
So let’s start ARNi for HFpEF post hospital follow up? https://t.co/jiNKutLnUk
https://t.co/jiNKutLnUk. I found the paper
RT @yulnunezvill: Sacubitril/valsartan en ICFEP. #AHA19 Paciente con ingreso reciente probablemente mayor beneficio @SVCardio @almucastro01…
RT @yulnunezvill: Sacubitril/valsartan en ICFEP. #AHA19 Paciente con ingreso reciente probablemente mayor beneficio @SVCardio @almucastro01…
RT @yulnunezvill: Sacubitril/valsartan en ICFEP. #AHA19 Paciente con ingreso reciente probablemente mayor beneficio @SVCardio @almucastro01…
RT @yulnunezvill: Sacubitril/valsartan en ICFEP. #AHA19 Paciente con ingreso reciente probablemente mayor beneficio @SVCardio @almucastro01…
RT @MAROSFO: the sooner the better? 📌 In the PARAGON-HF trial, relative and absolute benefits appear to be amplified when initiated in the…
RT @JACCJournals: @mvaduganathan presents PARAGON-HF substudy to packed audience at #AHA19: Benefits of sacubitril/valsartan (vs. valsartan…
RT @JACCJournals: @mvaduganathan presents PARAGON-HF substudy to packed audience at #AHA19: Benefits of sacubitril/valsartan (vs. valsartan…
RT @JACCJournals: @mvaduganathan presents PARAGON-HF substudy to packed audience at #AHA19: Benefits of sacubitril/valsartan (vs. valsartan…
RT @JACCJournals: @mvaduganathan presents PARAGON-HF substudy to packed audience at #AHA19: Benefits of sacubitril/valsartan (vs. valsartan…
RT @JACCJournals: @mvaduganathan presents PARAGON-HF substudy to packed audience at #AHA19: Benefits of sacubitril/valsartan (vs. valsartan…
@mvaduganathan presents PARAGON-HF substudy to packed audience at #AHA19: Benefits of sacubitril/valsartan (vs. valsartan) in #HFpEF appear to be amplified when initiated in high-risk window after hospitalization. In #JACC: https://t.co/XjWAEkZyYV @scottds
Sacubitril/valsartan en ICFEP. #AHA19 Paciente con ingreso reciente probablemente mayor beneficio @SVCardio @almucastro01 @ValleAlfonso @secardiologia https://t.co/sZeBHYxUEG
RT @MAROSFO: the sooner the better? 📌 In the PARAGON-HF trial, relative and absolute benefits appear to be amplified when initiated in the…
the sooner the better? 📌 In the PARAGON-HF trial, relative and absolute benefits appear to be amplified when initiated in the high-risk window after hospitalization https://t.co/KdMyue7Zo0 @JTLLERGO @yulnunezvill @Dr_Manito
RT @mvaduganathan: New #PARAGONHF data @AHAMeetings #AHA19 now online in @JACCJournals w/ @scottdsolomon Relative & absolute benefits of…
RT @mvaduganathan: New #PARAGONHF data @AHAMeetings #AHA19 now online in @JACCJournals w/ @scottdsolomon Relative & absolute benefits of…
RT @mvaduganathan: New #PARAGONHF data @AHAMeetings #AHA19 now online in @JACCJournals w/ @scottdsolomon Relative & absolute benefits of…
RT @mvaduganathan: New #PARAGONHF data @AHAMeetings #AHA19 now online in @JACCJournals w/ @scottdsolomon Relative & absolute benefits of…
RT @mvaduganathan: Importantly, #PARAGONHF allowed screening during 🏥 & 622 pts (13%) were enrolled within 30d of hospitalization ⚠️ Highe…
RT @pmyhre: Extremely important data from PARAGON-HF according to HF hospitalization status: RR 0.73 for patients hospitalized <30d (vs 1.0…
RT @mvaduganathan: New #PARAGONHF data @AHAMeetings #AHA19 now online in @JACCJournals w/ @scottdsolomon Relative & absolute benefits of…
RT @mvaduganathan: New #PARAGONHF data @AHAMeetings #AHA19 now online in @JACCJournals w/ @scottdsolomon Relative & absolute benefits of…
RT @mvaduganathan: New #PARAGONHF data @AHAMeetings #AHA19 now online in @JACCJournals w/ @scottdsolomon Relative & absolute benefits of…
RT @mvaduganathan: Importantly, #PARAGONHF allowed screening during 🏥 & 622 pts (13%) were enrolled within 30d of hospitalization ⚠️ Highe…
RT @mvaduganathan: New #PARAGONHF data @AHAMeetings #AHA19 now online in @JACCJournals w/ @scottdsolomon Relative & absolute benefits of…
RT @mvaduganathan: New #PARAGONHF data @AHAMeetings #AHA19 now online in @JACCJournals w/ @scottdsolomon Relative & absolute benefits of…
RT @mvaduganathan: New #PARAGONHF data @AHAMeetings #AHA19 now online in @JACCJournals w/ @scottdsolomon Relative & absolute benefits of…
RT @mvaduganathan: New #PARAGONHF data @AHAMeetings #AHA19 now online in @JACCJournals w/ @scottdsolomon Relative & absolute benefits of…
RT @mvaduganathan: New #PARAGONHF data @AHAMeetings #AHA19 now online in @JACCJournals w/ @scottdsolomon Relative & absolute benefits of…
RT @mvaduganathan: New #PARAGONHF data @AHAMeetings #AHA19 now online in @JACCJournals w/ @scottdsolomon Relative & absolute benefits of…
RT @mvaduganathan: New #PARAGONHF data @AHAMeetings #AHA19 now online in @JACCJournals w/ @scottdsolomon Relative & absolute benefits of…
RT @mvaduganathan: New #PARAGONHF data @AHAMeetings #AHA19 now online in @JACCJournals w/ @scottdsolomon Relative & absolute benefits of…
RT @mvaduganathan: New #PARAGONHF data @AHAMeetings #AHA19 now online in @JACCJournals w/ @scottdsolomon Relative & absolute benefits of…
RT @mvaduganathan: Importantly, #PARAGONHF allowed screening during 🏥 & 622 pts (13%) were enrolled within 30d of hospitalization ⚠️ Highe…
RT @mvaduganathan: New #PARAGONHF data @AHAMeetings #AHA19 now online in @JACCJournals w/ @scottdsolomon Relative & absolute benefits of…
RT @mvaduganathan: New #PARAGONHF data @AHAMeetings #AHA19 now online in @JACCJournals w/ @scottdsolomon Relative & absolute benefits of…
RT @mvaduganathan: New #PARAGONHF data @AHAMeetings #AHA19 now online in @JACCJournals w/ @scottdsolomon Relative & absolute benefits of…
RT @mvaduganathan: New #PARAGONHF data @AHAMeetings #AHA19 now online in @JACCJournals w/ @scottdsolomon Relative & absolute benefits of…
RT @mvaduganathan: New #PARAGONHF data @AHAMeetings #AHA19 now online in @JACCJournals w/ @scottdsolomon Relative & absolute benefits of…
RT @mvaduganathan: New #PARAGONHF data @AHAMeetings #AHA19 now online in @JACCJournals w/ @scottdsolomon Relative & absolute benefits of…
RT @mvaduganathan: New #PARAGONHF data @AHAMeetings #AHA19 now online in @JACCJournals w/ @scottdsolomon Relative & absolute benefits of…
RT @mvaduganathan: New #PARAGONHF data @AHAMeetings #AHA19 now online in @JACCJournals w/ @scottdsolomon Relative & absolute benefits of…
RT @mvaduganathan: New #PARAGONHF data @AHAMeetings #AHA19 now online in @JACCJournals w/ @scottdsolomon Relative & absolute benefits of…
RT @mvaduganathan: New #PARAGONHF data @AHAMeetings #AHA19 now online in @JACCJournals w/ @scottdsolomon Relative & absolute benefits of…
RT @mvaduganathan: New #PARAGONHF data @AHAMeetings #AHA19 now online in @JACCJournals w/ @scottdsolomon Relative & absolute benefits of…
RT @mvaduganathan: New #PARAGONHF data @AHAMeetings #AHA19 now online in @JACCJournals w/ @scottdsolomon Relative & absolute benefits of…
RT @mvaduganathan: New #PARAGONHF data @AHAMeetings #AHA19 now online in @JACCJournals w/ @scottdsolomon Relative & absolute benefits of…